Avx701 (Not yet branded)
Other Medications
Description
AVX701 is a cancer vaccine that uses a Venezuelan equine encephalitis virus replicon particle (VRP) platform to deliver the CEA(6D) antigen. This immunotherapy approach targets carcinoembryonic antigen (CEA), a tumor-associated antigen commonly overexpressed in colorectal cancer cells. The vaccine is designed to stimulate the patient's immune system to recognize and attack CEA-expressing cancer cells in both advanced metastatic disease and stage III colorectal cancer settings.
Mechanism of Action
The Venezuelan equine encephalitis virus replicon particle delivers the modified CEA(6D) antigen to antigen-presenting cells, which then process and present CEA epitopes to T-cells. This presentation activates both CD4+ and CD8+ T-cell responses against CEA-expressing tumor cells, creating a targeted immune response that can recognize and eliminate colorectal cancer cells displaying this tumor-associated antigen.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 Estado EMA | Experimental |
 Acceso España | med_spain_not_available |
| Administration | Intramuscular |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.